According to their research, a 24-h treatment with a concentration of 20 μM of Oroxylin A effectively hinder cell sustainability, migration, invasion, and epithelial-mesenchymal transition (EMT) by deactivating the NF-κB pathway in breast cancer cells. The gene discussed is NFKB1; the disease is breast cancer.